公开(公告)号：US20210247383A1

公开(公告)日：2021-08-12

申请号：US17156002

申请日：2021-01-22

Applicant: NOVARTIS AG

Inventor： Nelson Guerreiro ,  Christophe Meille ,  Jens Wuerthner

IPC: G01N33/50 ,  A61K31/496 ,  A61K31/47 ,  A61K31/4439 ,  A61K31/501 ,  A61P35/00

Abstract: The present disclosure relates to use of GDF-15 as a safety biomarker for determining a toxicological effect of a Mdm2 inhibitor; an ex vivo method for determining a toxicological effect of a Mdm2 inhibitor in a subject, in particular for determining a likelihood of developing thrombocytopenia in a subject in response to administration of a dose of a Mdm2 inhibitor; methods of using a Mdm2 inhibitor in the treatment of cancer in a subject; a kit for use in predicting the likelihood that a patient having cancer will develop thrombocytopenia in response to a treatment with a dose of a Mdm2 inhibitor; a kit for use in treating a patient having cancer and related disclosure embodiments.

公开(公告)号：US10935540B2

公开(公告)日：2021-03-02

申请号：US15749544

申请日：2016-08-03

Applicant: Novartis AG ,  Nelson Guerreiro ,  Christophe Meille ,  Jens Wuerthner

Inventor： Nelson Guerreiro ,  Christophe Meille ,  Jens Wuerthner

IPC: A61K31/496 ,  A61P35/00 ,  G01N33/50 ,  A61K31/47 ,  A61K31/4439 ,  A61K31/501

Abstract: The present disclosure relates to use of GDF-15 as a safety biomarker for determining a toxicological effect of a Mdm2 inhibitor; an ex vivo method for determining a toxicological effect of a Mdm2 inhibitor in a subject, in particular for determining a likelihood of developing thrombocytopenia in a subject in response to administration of a dose of a Mdm2 inhibitor; methods of using a Mdm2 inhibitor in the treatment of cancer in a subject; a kit for use in predicting the likelihood that a patient having cancer will develop thrombocytopenia in response to a treatment with a dose of a Mdm2 inhibitor; a kit for use in treating a patient having cancer and related disclosure embodiments.

公开(公告)号：US20220281970A1

公开(公告)日：2022-09-08

申请号：US17414211

申请日：2019-12-18

Applicant: Novartis AG

Inventor： Nelson Guerreiro ,  Ensar Halilovic ,  Astrid Jullion ,  Christophe Meille ,  Hui-Qin Wang ,  Claire Fabre

IPC: C07K16/28 ,  A61K31/506 ,  A61P35/02 ,  A61K39/395 ,  A61K45/06

Abstract: The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and an anti-TIM-3 antibody molecule as TIM-3 inhibitor. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment.

公开(公告)号：US20180224431A1

公开(公告)日：2018-08-09

申请号：US15749544

申请日：2016-08-03

Applicant: NOVARTIS AG

Inventor： Nelson Guerreiro ,  Christophe Meille ,  Jens Wuerthner

IPC: G01N33/50 ,  A61K31/496 ,  A61P35/00

Abstract: The present disclosure relates to use of GDF-15 as a safety biomarker for determining a toxicological effect of a Mdm2 inhibitor; an ex vivo method for determining a toxicological effect of a Mdm2 inhibitor in a subject, in particular for determining a likelihood of developing thrombocytopenia in a subject in response to administration of a dose of a Mdm2 inhibitor; methods of using a Mdm2 inhibitor in the treatment of cancer in a subject; a kit for use in predicting the likelihood that a patient having cancer will develop thrombocytopenia in response to a treatment with a dose of a Mdm2 inhibitor; a kit for use in treating a patient having cancer and related disclosure embodiments.

公开(公告)号：US20220331318A1

公开(公告)日：2022-10-20

申请号：US17642334

申请日：2020-09-14

Applicant: Novartis AG

Inventor： Asa Eliasson ,  Nelson Guerreiro ,  Christophe Meille ,  Hans Menssen ,  K Gary J Vanasse ,  Monika Wroclawska

IPC: A61K31/506 ,  A61K31/519 ,  A61P35/00

Abstract: The invention relates to the use of an MDM2 inhibitor in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an MDM2 inhibitor and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210255166A1

公开(公告)日：2021-08-19

申请号：US17155985

申请日：2021-01-22

Applicant: NOVARTIS AG

Inventor： Nelson Guerreiro ,  Christophe Meille ,  Jens Wuerthner

IPC: G01N33/50 ,  A61K31/496 ,  A61K31/47 ,  A61K31/4439 ,  A61K31/501 ,  A61P35/00

Abstract: The present disclosure relates to use of GDF-15 as a safety biomarker for determining a toxicological effect of a Mdm2 inhibitor; an ex vivo method for determining a toxicological effect of a Mdm2 inhibitor in a subject, in particular for determining a likelihood of developing thrombocytopenia in a subject in response to administration of a dose of a Mdm2 inhibitor; methods of using a Mdm2 inhibitor in the treatment of cancer in a subject; a kit for use in predicting the likelihood that a patient having cancer will develop thrombocytopenia in response to a treatment with a dose of a Mdm2 inhibitor; a kit for use in treating a patient having cancer and related disclosure embodiments.

公开(公告)号：US10966978B2

公开(公告)日：2021-04-06

申请号：US16461005

申请日：2017-11-14

Applicant: Novartis AG

Inventor： Stephane Ferretti ,  Nelson Guerreiro ,  Sebastien Jeay ,  Astrid Jullion ,  Christophe Meille ,  Jens Wuerthner

IPC: A61K31/497 ,  A61K31/505 ,  A61K31/506 ,  A61P7/00 ,  A61P35/02 ,  A61K45/06 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/4439 ,  A61P35/00 ,  A61K31/47 ,  A61K31/401 ,  A61K31/4152 ,  A61K31/496

Abstract: The present invention relates to HDM2-p53 interaction inhibitors for use in the treatment of cancer, wherein the drug is administered by a high dose intermittent dosing regimen. The present invention relates in particular to the HDM2-p53 interaction inhibitor HDM20I and the dosing regimen di, d8 of a 4 week cycle.

公开(公告)号：US20190298719A1

公开(公告)日：2019-10-03

申请号：US16461005

申请日：2017-11-14

Applicant: Novartis AG

Inventor： Stephane Ferretti ,  Nelson Guerreiro ,  Sebastien Jeay ,  Astrid Jullion ,  Christophe Meille ,  Jens Wuerthner

IPC: A61K31/506 ,  A61P7/00 ,  A61P35/02 ,  A61K45/06

Abstract: The present invention relates to HDM2-p53 interaction inhibitors for use in the treatment of cancer, wherein the drug is administered by a high dose intermittent dosing regimen. The present invention relates in particular to the HDM2-p53 interaction inhibitor HDM20I and the dosing regimen di, d8 of a 4 week cycle.